Shares of Becton, Dickinson and Co. (BDX) jumped 5.9% on Thursday after the medical technology company delivered second-quarter results that topped Wall Street expectations and raised its full-year earnings outlook. The stock was trading at $153.30 at the time of publication.

“We delivered a solid second quarter, with revenue, margins, and EPS all ahead of our expectations,” said Chairman, CEO, and President Tom Polen in a statement. He noted that more than 90% of the company’s business posted mid-single-digit growth.

For the quarter ended March 31, BD reported revenue of $4.71 billion, up 5.2% from the same period last year and ahead of the analyst consensus estimate of $4.67 billion. Adjusted earnings came in at $2.90 per share, topping the $2.77 per share that analysts had expected. The company also completed a $2 billion accelerated share repurchase program during the quarter, signaling confidence in its financial position.

Looking ahead, BD raised its fiscal 2026 adjusted earnings guidance to a range of $12.52 to $12.72 per share, up from the prior range of $12.35 to $12.65 per share. The updated outlook exceeds the consensus estimate of $12.48 per share. The company reaffirmed its revenue growth expectations for the full year, citing improved visibility for the remainder of the fiscal year based on first-half performance.

In a separate announcement, BD named Vitor Roque as executive vice president and chief financial officer, effective May 7. Roque had been serving as interim CFO since December 2025, so the move formalizes his role. The appointment provides stability in the finance leadership as the company navigates its growth trajectory.

Analyst Consensus & Recent Actions: Despite the upbeat results, Wall Street remains cautious on BD. The stock carries a consensus Hold rating with an average price target of $184.23. However, several analysts have recently trimmed their forecasts:

• TD Cowen: Hold (lowered forecast to $163.00) on May 4
• Piper Sandler: Neutral (lowered forecast to $159.00) on April 17
• Goldman Sachs: Neutral (forecast $167.00) on April 10

The lowered targets suggest that while BD’s execution has been solid, the broader market or sector headwinds may still be a concern. Still, the company’s ability to beat estimates and raise guidance is a positive signal for investors.